Capricor Therapeutics
CAPR
Market cap $653M

18.49 USD

-2.02

9.85%

At close Oct 17, 4:00 PM EDT

Pre-market

18.50

+0.01

0.05%

1 day

-9.85%

5 days

1.20%

1 month

263.98%

3 months

283.61%

6 months

233.15%

Year to date

261.13%

1 year

551.06%

5 years

582.29%

About: Capricor Therapeutics Inc is a United States-based biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy and other medical conditions. The company's development stage product pipeline includes CAP-1002, for Duchenne Muscular Dystrophy Program and COVID-19 Program; CDC-Exosomes (CAP-2003); and Exosome-mRNA vaccine.

Employees: 102

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,740 funds

0

Analysts bullish %

of 10 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

29% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 17

13% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 16

9% more funds holding

Funds holding: 56 [Q1] → 61 (+5) [Q2]

4.39% more ownership

Funds ownership: 15.7% [Q1] → 20.1% (+4.39%) [Q2]

8% less capital invested

Capital invested by funds: $33.5M [Q1] → $30.7M (-$2.82M) [Q2]

26% less call options, than puts

Call options by funds: $1.36M | Put options by funds: $1.84M

See Fund Rankings

Research analyst outlook

10 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$8

57%

downside

Avg. target

$32

70%

upside

High target

$77

316%

upside

10 analyst ratings

10 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Joseph Pantginis 36% 1-year accuracy 92 / 257 met price target	316%upside $77	Buy Maintained	11 Oct 2024
HC Wainwright & Co. Joseph Pantginis 36% 1-year accuracy 92 / 257 met price target	116%upside $40	Buy Reiterated	9 Oct 2024
Oppenheimer Leland Gershell 58% 1-year accuracy 30 / 52 met price target	133%upside $43	Outperform Maintained	25 Sept 2024
Maxim Group Jason McCarthy 44% 1-year accuracy 8 / 18 met price target	35%upside $25	Buy Maintained	25 Sept 2024
HC Wainwright & Co. Joseph Pantginis 36% 1-year accuracy 92 / 257 met price target	116%upside $40	Buy Reiterated	24 Sept 2024

See Analyst Rankings

Financial journalist opinion

Based on 13 articles about CAPR published over the past 30 days

Capricor Therapeutics Announces Pricing of Approximately $75 Million Public Offering of Common Stock

SAN DIEGO, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced the pricing of its underwritten offering of 4,412,000 shares of common stock at a public offering price of $17.00 per share. Capricor also granted the underwriters a 30-day option to purchase up to an additional 661,800 shares of its common stock at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on October 18, 2024, subject to the satisfaction of customary closing conditions.

Capricor Therapeutics Announces Pricing of Approximately $75 Million Public Offering of Common Stock

Capricor Therapeutics Announces Proposed Public Offering of Common Stock

SAN DIEGO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced the commencement of a proposed underwritten public offering of shares of its common stock. In addition, Capricor intends to grant the underwriters a 30-day option to purchase an additional number of shares of common stock equal to 15% of the aggregate number of shares of its common stock sold in the public offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Capricor Therapeutics Announces Proposed Public Offering of Common Stock

Capricor Therapeutics Announces Positive Long-Term Data from HOPE-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society Congress

-Data Supports Deramiocel's Sustained Efficacy and Safety in Treating DMD- -Improvements Seen in Multiple Cardiac and Skeletal Endpoints Demonstrating Stabilization of Cardiac and Skeletal Muscle Function Over 3 Years of Treatment- -Company on Track to Fully Submit Biologics License Application (BLA) by End of 2024- SAN DIEGO, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced positive 3-year safety and efficacy results from its ongoing HOPE-2 open label extension (OLE) study for its lead asset, deramiocel, for the treatment of Duchenne muscular dystrophy (DMD). The data was highlighted in a late-breaking poster presentation at the 29th Annual Congress of the World Muscle Society (WMS), October 8-12, 2024 in Prague, Czechia.

Capricor Therapeutics Announces Positive Long-Term Data from HOPE-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society Congress

Zacks Investment Research

What Makes Capricor (CAPR) a Good Fit for 'Trend Investing'

If you are looking for stocks that are well positioned to maintain their recent uptrend, Capricor (CAPR) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

What Makes Capricor (CAPR) a Good Fit for 'Trend Investing'

Capricor Therapeutics Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

-Company Plans to Complete Rolling BLA Submission by End of 2024; Application May be Eligible for Priority Review by FDA-

Capricor Therapeutics Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

Zacks Investment Research

Does Capricor (CAPR) Have the Potential to Rally 90.16% as Wall Street Analysts Expect?

The mean of analysts' price targets for Capricor (CAPR) points to a 90.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Does Capricor (CAPR) Have the Potential to Rally 90.16% as Wall Street Analysts Expect?

Capricor Therapeutics to Present Long-Term Data from HOPE-2 Open Label Extension Study at 2024 World Muscle Society Congress

SAN DIEGO, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, announced today that the Company will present the three-year safety and efficacy results from its HOPE-2 open-label extension (OLE) study with lead asset deramiocel for treating Duchenne muscular dystrophy (DMD). The data will highlight the long-term, multi-modal benefits of deramiocel in a late-breaking poster presentation at the 29th Annual Congress of the World Muscle Society (WMS 2024), taking place October 8-12, 2024, in Prague, Czechia.

Capricor Therapeutics to Present Long-Term Data from HOPE-2 Open Label Extension Study at 2024 World Muscle Society Congress

Capricor Therapeutics Is Up Over 100%, Could Rise Even Higher

Capricor Therapeutics Inc. CAPR is a biotechnology firm focused on developing cell and exosome-based treatments for rare diseases like Duchenne muscular dystrophy (DMD). Capricor's stock surged more than 100% after announcing it will pursue full FDA approval for its primary drug deramiocel (CAP-1002) in this year.

Capricor Therapeutics Is Up Over 100%, Could Rise Even Higher

Capricor Therapeutics is up over 100%, Could Rise Even Higher

Capricor Therapeutics Inc. NASDAQ: CAPR is a biotechnology firm focused on developing cell and exosome-based treatments for rare diseases like Duchenne muscular dystrophy (DMD). Capricor's stock surged more than 100% after announcing it will pursue full FDA approval for its primary drug deramiocel (CAP-1002) in this year.

Capricor Therapeutics is up over 100%, Could Rise Even Higher

24/7 Wall Street

Check Out Last Week's Big Insider Buying: Biotechs, Energy, and More

24/7 Wall St. Insights Summer gave way to autumn this past week, and notable insider buying continued.

Check Out Last Week's Big Insider Buying: Biotechs, Energy, and More

See News Rankings

Charts implemented using Lightweight Charts™